[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2009003815A - Pharmaceutical formulations. - Google Patents

Pharmaceutical formulations.

Info

Publication number
MX2009003815A
MX2009003815A MX2009003815A MX2009003815A MX2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
active agent
formulation
dissolution
salt
Prior art date
Application number
MX2009003815A
Other languages
Spanish (es)
Inventor
Dennis Y Lee
Yi Gao
R Ju Tzuchi
Nicole Nguyen
Hauiliang Wu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009003815A publication Critical patent/MX2009003815A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media.
MX2009003815A 2006-10-12 2007-10-12 Pharmaceutical formulations. MX2009003815A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12
PCT/US2007/081267 WO2008046052A1 (en) 2006-10-12 2007-10-12 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MX2009003815A true MX2009003815A (en) 2009-09-07

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003815A MX2009003815A (en) 2006-10-12 2007-10-12 Pharmaceutical formulations.

Country Status (14)

Country Link
EP (1) EP2081563A1 (en)
JP (1) JP2010506855A (en)
KR (1) KR20090119959A (en)
CN (1) CN101677981A (en)
AU (1) AU2007307641A1 (en)
CA (1) CA2672686A1 (en)
CO (1) CO6160302A2 (en)
EA (1) EA200900531A1 (en)
EC (1) ECSP099251A (en)
IL (1) IL198160A0 (en)
MX (1) MX2009003815A (en)
SG (1) SG175570A1 (en)
WO (1) WO2008046052A1 (en)
ZA (1) ZA200902488B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2285357T3 (en) * 2008-05-30 2014-06-02 Ucb Pharma Sa Pharmaceutical composition comprising brivaracetam
CN102304103A (en) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 Fenofibrate acid salt, preparation method, pharmaceutical composition and application
CN102659570B (en) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 Difluoro fenofibrate acid and pharmaceutically acceptable salt thereof as well as preparation method and application thereof
FR3050112B1 (en) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq USE OF FENOFIBRIC ACID IN THE TREATMENT OF HEPATIC DISEASES
CN107496397A (en) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 A kind of compound and its preparation of melbine and Fenofibric Acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832285A1 (en) * 2002-12-17 2007-09-12 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
MXPA05005736A (en) * 2002-12-17 2005-08-16 Abbott Gmbh & Co Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof.
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
SG161256A1 (en) * 2005-04-08 2010-05-27 Abbott Lab Oral pharmaceutical formulations comprising fenofibric acid and/or its salts

Also Published As

Publication number Publication date
EP2081563A1 (en) 2009-07-29
EA200900531A1 (en) 2009-12-30
IL198160A0 (en) 2009-12-24
KR20090119959A (en) 2009-11-23
ECSP099251A (en) 2009-06-30
SG175570A1 (en) 2011-11-28
CN101677981A (en) 2010-03-24
CA2672686A1 (en) 2008-04-17
CO6160302A2 (en) 2010-05-20
WO2008046052A1 (en) 2008-04-17
JP2010506855A (en) 2010-03-04
AU2007307641A1 (en) 2008-04-17
ZA200902488B (en) 2010-10-27

Similar Documents

Publication Publication Date Title
MX350380B (en) Zero-order modified release solid dosage forms.
MX2008000099A (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof.
WO2010057036A3 (en) Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
WO2008137758A3 (en) Amino acid lipids and uses thereof
IN2012DN01216A (en)
HK1140972A1 (en) Novel agent for releasing active principles in dressings containing at least one fatty substance
WO2007036952A3 (en) Novel sustained release dosage form
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
EP1713450A4 (en) Rapidly dissolving film for delivery of an active agent
MX2009013019A (en) Modifying drug release in suspensions of ionic resin systems.
NZ610701A (en) Once daily formulation of lacosamide
WO2006116718A3 (en) Pharma-informatics system
WO2010068281A3 (en) Contact lens drug delivery device
WO2009060608A1 (en) Sustained release composition containing sdf-1
PT2043600T (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
PT1834635E (en) Stable nanocapsule systems for the administration of active molecules
WO2007008220A3 (en) Gene or drug delivery system
WO2007095041A3 (en) Pharmaceutical formulations
MX2009006447A (en) Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate.
MX2009003815A (en) Pharmaceutical formulations.
WO2011101866A3 (en) Gastric retention formulation containing baclofen
WO2009047802A3 (en) Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
MX2013001985A (en) Nalbuphine-based formulations and uses thereof
PT1795186E (en) Flupirtin comprising medicament formulation with a controlled release of the active agent

Legal Events

Date Code Title Description
FA Abandonment or withdrawal